Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Fig. 1

Intratumoral heterogeneity alone or combined with TMB is associated with clinical outcome in SYSUCC NSCLC cohort. a Distribution of intratumoral heterogeneity (ITH) in SYSUCC NSCLC cohort. Top histogram, counts of clonal mutation (indigo) and subclonal mutation (green) of each patient; lower histogram, proportion clonal mutation and subclonal mutation of each patient. b Boxplots of the distribution of ITH value between patients with DCB and NDB, and the distribution of ITH between patients with objective response (ORR) and non-object response (NOR). c Barplots of DCB rate and ORR between ITH-L group and ITH-H group. d ITH-L is associated with better progression-free survival. e The correlation between ITH and TMB. f ITH-L is associated with better progress-free survival in TMB-L subgroup. g Barplot of durable clinical benefit rate among three groups of TMB-H, TMB-L&ITH-L and TMB-L&ITH-H. h Progression-free survival plot among three groups of TMB-H, TMB-L&ITH-L and TMB-L&ITH-H

Back to article page

Molecular Cancer

ISSN: 1476-4598